These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 32678719

  • 1. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [Abstract] [Full Text] [Related]

  • 2. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 3. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [Abstract] [Full Text] [Related]

  • 4. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T.
    J Comp Eff Res; 2019 Nov; 8(15):1299-1316. PubMed ID: 31559852
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 6. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
    Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT.
    Int J Chron Obstruct Pulmon Dis; 2023 Nov; 18():625-641. PubMed ID: 37155497
    [Abstract] [Full Text] [Related]

  • 7. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
    Buhl R, Dreher M, Mattiucci-Guehlke M, Emerson-Stadler R, Eckhardt S, Taube C, Vogelmeier CF.
    Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J.
    Respir Res; 2017 Nov 25; 18(1):196. PubMed ID: 29178871
    [Abstract] [Full Text] [Related]

  • 9. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol.
    Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF.
    Int J Chron Obstruct Pulmon Dis; 2020 Nov 25; 15():2601-2608. PubMed ID: 33122898
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
    Quint JK, Montonen J, Esposito DB, He X, Koerner L, Wallace L, de la Hoz A, Miravitlles M.
    Adv Ther; 2021 May 25; 38(5):2249-2270. PubMed ID: 33721209
    [Abstract] [Full Text] [Related]

  • 11. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov 25; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 12. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
    Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.
    BMC Pulm Med; 2021 Jul 31; 21(1):253. PubMed ID: 34332555
    [Abstract] [Full Text] [Related]

  • 13. Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
    Muro S, Suzuki M, Nakamura S, Wang JR, Garry EM, Sakamoto W, de Souza S.
    Respir Res; 2021 Jun 17; 22(1):180. PubMed ID: 34140019
    [Abstract] [Full Text] [Related]

  • 14. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
    Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH.
    Respir Med; 2018 Jun 17; 139():65-71. PubMed ID: 29858004
    [Abstract] [Full Text] [Related]

  • 15. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
    Derom E, Brusselle GG, Joos GF.
    Ther Adv Respir Dis; 2019 Jun 17; 13():1753466619843426. PubMed ID: 31002020
    [Abstract] [Full Text] [Related]

  • 16. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 17. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC, Stemkowski S, Stanford RH, Tao Z.
    J Manag Care Spec Pharm; 2018 Nov 06; 24(11):1165-1172. PubMed ID: 30362922
    [Abstract] [Full Text] [Related]

  • 18. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR, Zhou S, Shaikh A, Willey VJ.
    J Manag Care Spec Pharm; 2021 May 06; 27(5):625-637. PubMed ID: 33779246
    [Abstract] [Full Text] [Related]

  • 19. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.
    Choi KY, Kim HI, Rhee CK, Yoo KH, Park YB, Kim Y, Lee SE, Kim JA, Hwang YI.
    Int J Chron Obstruct Pulmon Dis; 2024 May 06; 19():1661-1671. PubMed ID: 39050737
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M, Kunita Y, Shirahase K, Yamazaki R, Hanada S, Sawaguchi H, Tohda Y.
    BMC Pulm Med; 2021 Jan 13; 21(1):26. PubMed ID: 33441146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.